Cybin & The Chopra Foundation Recognize World Mental Health Day

-- Cybin and The Chopra Foundation continue to work together to advance the research and education of psychedelic-based therapeutics as a new paradigm for the treatment of mental health --

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ^® , and The Chopra Foundation ("Foundation"), a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, join everyone in recognizing World Mental Health Day. The two organizations continue to work toward the research and education of psychedelic-based therapies and their role in enhancing well-being and consciousness.

According to the World Health Organization ("WHO"), over 900 million people are affected by mental illness around the world. The pandemic has increased the number of individuals that are affected by different forms of mental illness. In 2021 the WHO released data that over 280 million people were affected by depression.

"World Mental Health Day sends a reminder that our mental health is just as important as our physical health," said Doug Drysdale, Cybin's Chief Executive Officer. "At Cybin, mental health and well-being is at the center of everything that we do. It's this value that drives us to invest our energy and resources to discover new and innovative treatment options for mental health conditions. The commitment from organizations like The Chopra Foundation plays a critical role in this goal, and we are proud to partner with the Foundation to continue to educate and support what is possible for the treatment of mental health from psychedelics."

This year's World Mental Health Day theme is "Make Mental Health and Well-Being for All a Global Priority," and marks an opportunity for people with mental health conditions, advocates, governments, employers, employees and other stakeholders to come together to recognize progress in the field and to be vocal about what is needed to ensure mental health and well-being becomes a global priority for all. These initiatives are at the forefront of the work that Cybin and The Chopra Foundation are doing together to ensure that everyone has access to well-being resources, including those in underserved communities. An example of these initiatives is through The Chopra Foundation's Never Alone movement.

"The Chopra Foundation is committed to working with Cybin for creative and holistic solutions for alleviating the immense human suffering from mental disorders," said Deepak Chopra, The Chopra Foundation Founder, Chairman of the Board and Director. "Psychedelics research, creating support communities, emotional AI, and love in action through NeverAlone.love are just some of the areas we are working together on."

"On World Mental Health Day we recognize the urgency and desperate need to provide resources to those that are suffering. For that, we are grateful for the collaboration between Cybin and the Chopra Foundation, which is meaningful on multiple levels," said Poonacha Machaiah, Chief Executive Officer of The Chopra Foundation. "Mental health and longevity are core pillars of the Chopra Foundation, and we look forward to continuing to create an impact through our partnership with Cybin."

About The Chopra Foundation and Never Alone

The Chopra Foundation is a 501 (c) (3) organization (#36-4793898) dedicated to improving health and well-being, cultivating spiritual knowledge, expanding consciousness, and promoting world peace to all members of the human family. The Foundation's Never Alone movement will be providing the world with the tools to proactively pursue their path to joy and freedom from suffering.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005183/en/

Media Inquiries for The Chopra Foundation:
Kristen Marion
kristen@marionpr.com
623-308-2638

Investor & Media Inquiries for Cybin:
Leah Gibson
Vice President, Investor Relations & Strategic Communications
Cybin Inc.
irteam@cybin.com – or – media@cybin.com

Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601

News Provided by Business Wire via QuoteMedia

Cybin Inc.CYBN NYSEAMERICAN:CYBN Life Science Investing

CYBN

Trippy Trading: Top Psychedelic Stocks For 2023

(NewsDirect)

When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scientists are once again investigating psychedelics and other mind-altering substances such as MDMA, psilocybin, and ketamine as treatments for depression, PTSD, anxiety, and other mental health conditions.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting

- New findings underscore potential of CYB003 as a novel psychedelic-based therapeutic for the treatment of depression -

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ^® , today announced that the Company presented two posters on its deuterated psilocybin analog, CYB003, at the American College of Neuropsychopharmacology ("ACNP") annual meeting taking place December 4-7, 2022, in Phoenix, Arizona. The data presented, including new pharmacokinetics ("PK") findings, further strengthen the therapeutic profile of CYB003 as a novel treatment for major depressive disorder ("MDD").

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Cybin's EMBARK Program Announces Graduation of Facilitators

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics ^® ", today announced the graduation of highly-skilled facilitators from its EMBARK Psychedelic-Assisted Psychotherapy Training Program.

EMBARK is a leading-edge model of psychedelic-assisted psychotherapy co-developed by Alex Belser, Ph.D., and Bill Brennan, Ph.D. The EMBARK model is currently being implemented in two clinical-stage trials, including Cybin's Phase 1/2a trial evaluating the Company's investigational deuterated psilocybin analog, CYB003, designed to be a faster-acting, shorter duration treatment for major depressive disorder ("MDD").

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Cybin & The Chopra Foundation Recognize World Mental Health Day

-- Cybin and The Chopra Foundation continue to work together to advance the research and education of psychedelic-based therapeutics as a new paradigm for the treatment of mental health --

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ^® , and The Chopra Foundation ("Foundation"), a not-for-profit organization dedicated to improving health and well-being founded by Dr. Deepak Chopra, join everyone in recognizing World Mental Health Day. The two organizations continue to work toward the research and education of psychedelic-based therapies and their role in enhancing well-being and consciousness.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Cybin Provides Update on its Intellectual Property Portfolio

-- Cybin strengthens its intellectual property library with more than 20 active patent filings across six patent families, and multiple license agreements that provide access to over 35 patents and applications --

Cybin Inc. ( NEO:CYBN ) (NYSE AMERICAN:CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics ^® , is pleased to provide an update on its intellectual property ("IP") progress in support of its research and development strategy. The Company continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Viemed Healthcare Announces Date and Time for Conference Call

Viemed Healthcare, Inc. (the " Company " or " Viemed ") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced today that it will host its Quarterly Conference Call on Tuesday, May 7, 2024 at 11:00 a.m. ET.

Interested parties may participate in the call by dialing:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

Viemed Healthcare, Inc. (the "Company" or "Viemed") (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health ("EAH"), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama.

"We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand HomeMed's business through the strategic partnership," said Viemed Chief Executive Officer Casey Hoyt. "This marks a significant milestone in our ongoing growth strategy, which includes hospital joint ventures and institutional partnerships. We view this transaction as a blueprint that can be replicated nationwide, enhancing care quality while simultaneously creating value for healthcare systems."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Execution of Variation to Facility Agreement with PURE Asset Management, Company to Seek a Sale Transaction

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (Hydralyte North America or the Company) advises that today it has signed a variation to its facility agreement with boutique asset manager and existing substantial shareholder PURE Asset Management Pty Ltd as trustee for The Income and Growth Fund (PURE or PURE Asset Management) as previously announced to the market on 17 October 2022 (Original PURE Facility).

Keep reading...Show less

Viemed Healthcare, INC. CONSOLIDATED BALANCE SHEETS *(Expressed in thousands of U.S. Dollars, except share amounts)*
	At December 31, 2023		At December 31, 2022
ASSETS
Current assets
Cash and cash equivalents	$	12,839	$	16,914
Accounts receivable, net		18,451		15,379
Inventory		4,628		3,574
Income tax receivable		—		26
Prepaid expenses and other assets		2,449		3,849
Total current assets	$	38,367	$	39,742
Long-term assets
Property and equipment, net		73,579		67,743
Finance lease right-of-use assets		401		—
Operating lease right-of-use assets		2,872		694
Equity investments		1,680		2,155
Debt investment		2,219		2,000
Deferred tax asset		4,558		3,119
Identifiable intangibles, net		567		—
Goodwill		29,765		—
Other long-term assets		887		1,590
Total long-term assets		116,528		77,301
TOTAL ASSETS	$	154,895	$	117,043

LIABILITIES
Current liabilities
Trade payables	$	4,180	$	2,650
Deferred revenue		6,207		4,624
Income taxes payable		2,153		—
Accrued liabilities		17,578		11,092
Finance lease liabilities, current portion		256		—
Operating lease liabilities, current portion		678		495
Current debt		1,072		—
Total current liabilities	$	32,124	$	18,861
Long-term liabilities
Accrued liabilities		558		889
Finance lease liabilities, less current portion		132		—
Operating lease liabilities, less current portion		2,184		199
Long-term debt		6,002		—
Total long-term liabilities	$	8,876	$	1,088
TOTAL LIABILITIES	$	41,000	$	19,949

Commitments and Contingencies		—		—

SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,506,161 and 38,049,739 issued and outstanding as of December 31, 2023 and December 31, 2022, respectively		18,702		15,123
Additional paid-in capital		15,698		12,125
Retained earnings		79,495		69,846
TOTAL SHAREHOLDERS' EQUITY	$	113,895	$	97,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	154,895	$	117,043

Viemed Healthcare, INC. CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME *(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)*
	Three Months Ended December 31,						Year Ended December 31,
		2023			2022			2023			2022
Revenue	$	50,739		$	37,508		$	183,008		$	138,832

Cost of revenue		18,628			14,612			70,225			54,152

Gross profit	$	32,111		$	22,896		$	112,783		$	84,680

Operating expenses
Selling, general and administrative		23,905			17,172			87,884			68,161
Research and development		651			722			2,782			2,696
Stock-based compensation		1,534			1,317			5,849			5,202
Depreciation and amortization		434			241			1,391			1,012
Loss on disposal of property and equipment		272			178			645			346
Other income, net		26			(268	)		(98	)		(989	)
Income from operations	$	5,289		$	3,534		$	14,330		$	8,252

Non-operating income and expenses
Income from equity method investments		43			82			485			935
Interest expense, net		(256	)		(32	)		(424	)		(197	)

Net income before taxes		5,076			3,584			14,391			8,990
Provision for income taxes		1,599			1,146			4,148			2,768

Net income	$	3,477		$	2,438		$	10,243		$	6,222

Other comprehensive income
Change in unrealized gain/loss on derivative instruments, net of tax		—			(56	)		—			278
Other comprehensive income	$	—		$	(56	)	$	—		$	278

Comprehensive income	$	3,477		$	2,382		$	10,243		$	6,500

Net income per share
Basic	$	0.09		$	0.06		$	0.27		$	0.16
Diluted	$	0.09		$	0.06		$	0.25		$	0.16

Weighted average number of common shares outstanding:
Basic		38,492,731			38,015,795			38,354,071			38,655,403
Diluted		40,383,109			39,513,158			40,378,922			39,807,434

Viemed Healthcare, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS *(Expressed in thousands of U.S. Dollars)*
	Year Ended December 31,
		2023			2022
Cash flows from operating activities
Net income	$	10,243		$	6,222
Adjustments for:
Depreciation and amortization		21,862			15,630
Change in inventory reserve		—			(1,418	)
Stock-based compensation expense		5,849			5,202
Distributions of earnings received from equity method investments		980			1,079
Income from equity method investments		(485	)		(935	)
Income from debt investment		(219	)		—
Loss on disposal of property and equipment		645			346
Deferred income tax (benefit) expense		(1,439	)		1,746
Changes in working capital, net of effects from acquisitions:
Accounts receivable, net		(1,058	)		(2,556	)
Inventory		(472	)		301
Prepaid expenses and other assets		2,176			(2,838	)
Trade payables		(859	)		(318	)
Deferred revenue		851			871
Accrued liabilities		4,959			2,549
Income tax payable/receivable		2,179			1,867
Net cash provided by operating activities	$	45,212		$	27,748

Cash flows from investing activities
Purchase of property and equipment		(26,093	)		(22,898	)
Investment in equity investments		(20	)		(141	)
Cash paid for acquisition of HMP, net of cash acquired		(28,588	)		—
Investment in debt security		—			(2,000	)
Proceeds from sale of property and equipment		2,588			1,063
Net cash used in investing activities	$	(52,113	)	$	(23,976	)

Cash flows from financing activities
Proceeds from exercise of options		1,303			283
Proceeds from term notes		5,000			—
Principal payments on term notes		(3,721	)		(5,796	)
Proceeds from revolving credit facilities		8,000			—
Payments on revolving credit facilities		(7,005	)		—
Shares redeemed to pay income tax		(594	)		(143	)
Shares repurchased under the share repurchase program		—			(9,568	)
Repayments of lease liabilities		(157	)		(42	)
Net cash provided by (used in) financing activities	$	2,826		$	(15,266	)

Net decrease in cash and cash equivalents		(4,075	)		(11,494	)
Cash and cash equivalents at beginning of year		16,914			28,408
Cash and cash equivalents at end of period	$	12,839		$	16,914

Supplemental disclosures of cash flow information
Cash paid during the period for interest	$	851		$	231
Cash paid (received) during the period for income taxes, net of refunds	$	3,566		$	(846	)
Supplemental disclosures of non-cash transactions
Non-cash change in debt from the reclassification of debt issuance costs	$	(594	)	$	—
Net non-cash changes to operating lease	$	(41	)	$	530

Viemed Healthcare, INC. Reconciliation of Net Income to Non-GAAP Adjusted EBITDA *(Expressed in thousands of U.S. Dollars)* *(Unaudited)*
For the quarter ended	December 31, 2023		September 30, 2023		June 30, 2023			March 31, 2023			December 31, 2022		September 30, 2022		June 30, 2022		March 31, 2022
Net Income	$	3,477	$	2,919	$	2,330		$	1,517		$	2,438	$	1,055	$	967	$	1,762
Add back:
Depreciation & amortization		5,918		5,975		5,207			4,762			4,373		4,120		3,740		3,397
Interest expense (income)		256		237		(20	)		(49	)		32		42		59		64
Stock-based compensation ^(a)		1,534		1,453		1,471			1,391			1,317		1,309		1,271		1,305
Transaction costs ^(b)		61		177		94			206			—		—		—		—
Income tax expense		1,599		1,320		728			501			1,146		456		421		745
Adjusted EBITDA	$	12,845	$	12,081	$	9,810		$	8,328		$	9,306	$	6,982	$	6,458	$	7,273

	Year Ended December 31, 2023
Net Income	$	10,243
Add back:
Depreciation & amortization		21,862
Interest expense (income)		424
Stock-based compensation ^(a)		5,849
Transaction costs ^(b)		538
Income tax expense		4,148
Adjusted EBITDA	$	43,064

(in thousands)	Three Months Ended December 31,						Year Ended December 31,
		2023			2022			2023			2022
Net cash provided by operating activities	$	13,284		$	7,684		$	45,212		$	27,748
Purchase of property and equipment		(7,932	)		(5,572	)		(26,093	)		(22,898	)
Free Cash Flow	$	5,352		$	2,112		$	19,119		$	4,850

Viemed Healthcare, INC. Key Financial and Operational Information *(Expressed in thousands of U.S. Dollars, except vent patients)* *(Unaudited)*
For the quarter ended	December 31, 2023			September 30, 2023			June 30, 2023			March 31, 2023			December 31, 2022			September 30, 2022			June 30, 2022			March 31, 2022
Financial Information:
Revenue	$	50,739		$	49,402		$	43,311		$	39,556		$	37,508		$	35,759		$	33,310		$	32,255
Gross Profit		32,111			30,562			26,106			24,004			22,896			21,651			20,390			19,743
Gross Profit %		63	%		62	%		60	%		61	%		61	%		61	%		61	%		61	%
Net Income		3,477			2,919			2,330			1,517			2,438			1,055			967			1,762
Cash and Cash Equivalents (As of)		12,839			10,078			10,224			23,544			16,914			21,478			21,922			29,248
Total Assets (As of)		154,895			149,400			149,117			124,634			117,043			119,419			115,904			119,007
Adjusted EBITDA ⁽¹⁾		12,845			12,081			9,810			8,328			9,306			6,982			6,458			7,273
Operational Information:
Vent Patients ⁽²⁾		10,327			10,244			10,005			9,337			9,306			9,127			8,837			8,434

Cybin & The Chopra Foundation Recognize World Mental Health Day

Contact Details

Company Website

1. UnitedHealth Group (NYSE:UNH)

2. Thermo Fisher Scientific (NYSE:TMO)

3. Abbott Laboratories (NYSE:ABT)

4. Intuitive Surgical (NASDAQ:ISRG)

5. Stryker (NYSE:SYK)

Latest News

Latest Press Releases

Related News

TOP STOCKS